Sarepta Therapeutics, Inc. (SRPT)

Market Cap	12.54B
Revenue (ttm)	1.40B
Net Income (ttm)	16.90M
Shares Out	94.52M
EPS (ttm)	0.40
PE Ratio	331.65
Forward PE	28.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,205,845
Open	133.55
Previous Close	131.70
Day's Range	130.89 - 134.34
52-Week Range	55.25 - 154.00
Beta	0.95
Analysts	Buy
Price Target	163.63 (+23.35%)
Earnings Date	May 1, 2024

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,314
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT

Financial Performance

In 2023, SRPT's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $163.63, which is an increase of 23.35% from the latest price.

Price Target

$163.63

(23.35% upside)

Analyst Consensus: Buy